Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.59 |
| ▸ | CES1 | P23141 | 3/20 | 0.52 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.50 |
| ▸ | PPARG | P37231 | 2/20 | 0.50 |
| ▸ | PPARD | Q03181 | 2/20 | 0.50 |
| ▸ | PPARA | Q07869 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.50 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.50 |
| ▸ | TLR2 | O60603 | 1/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16008252 | 1.00 | CES2 (0.59) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL9465217 | 1.00 | CES2 (0.59) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL3939399 | 1.00 | CES2 (0.59) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL9463727 | 1.00 | CES2 (0.59) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL5936351 | 1.00 | CES2 (0.59) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL2734730 | 1.00 | CES2 (0.59) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL9054385 | 1.00 | CES2 (0.59) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL9463930 | 1.00 | CES2 (0.59) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL9057797 | 1.00 | CES2 (0.59) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL5936374 | 1.00 | CES2 (0.59) | CES2CES1GPR84PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122028939-A | Thyroid hormone delivery system comprising lipid or polymer nanoparticles | 里卡尔多·泰尔齐与西尔维奥·阿尔比尼基金会 | 2026-05-12 | — | — | CN | claimed |
| WO-2023240156-A9 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES, AND METHODS OF SYNTHESIS AND USE THEREOF | TIDAL THERAPEUTICS, INC. (US) | 2024-04-18 | — | — | WO | claimed |
| CN-116407625-A | Lipid nanoparticle for enhancing nucleic acid immunity efficacy and preparation method and application thereof | 四川大学华西医院 | 2023-07-11 | — | — | CN | claimed |
| WO-2023083086-A1 | DRUG-COATED AND DRUG-ELUTING BALLOON CATHETER, AND PREPARATION METHOD THEREFOR | 上海博脉安医疗科技有限公司 | 2023-05-19 | — | — | WO | claimed |
| CN-122028939-A | Thyroid hormone delivery system comprising lipid or polymer nanoparticles | 里卡尔多·泰尔齐与西尔维奥·阿尔比尼基金会 | 2026-05-12 | — | — | CN | disclosed |
| EP-4658313-A1 | HSC-SPECIFIC ANTIBODY CONJUGATED LIPID NANOPARTICLES AND USES THEREOF | GENZYME CORPORATION (US) | 2025-12-10 | — | — | EP | disclosed |
| WO-2025064401-A9 | NUCLEASE RESISTANT SINGLE STRANDED DNA PRODUCT FOR NON-VIRAL DELIVERY TO A CELL AND METHODS OF PRODUCTION THEREOF | INTELLIA THERAPEUTICS, INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| EP-4602026-A1 | NOVEL IONIZABLE LIPIDS | Ribopro B.V. (NL) | 2025-08-20 | — | — | EP | disclosed |
| WO-2025149656-A1 | TREATMENT AND PREVENTION OF LUNG CANCER | CANCER RESEARCH TECHNOLOGY LTD (GB) | 2025-07-17 | — | — | WO | disclosed |
| WO-2025128902-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES, AND METHODS OF SYNTHESIS AND USE THEREOF | TIDAL THERAPEUTICS, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| EP-4536294-A1 | METHOD FOR SUSTAINED DELIVERY OF MRNA VACCINES | Merck Sharp & Dohme LLC (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2025064401-A1 | NUCLEASE RESISTANT SINGLE STRANDED DNA PRODUCT FOR NON-VIRAL DELIVERY TO A CELL AND METHODS OF PRODUCTION THEREOF | INTELLIA THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| EP-0235259-B1 | NOVEL TRANSDERMAL ANTI-ANGINAL PHARMACEUTICAL DOSAGE UNIT AND PROCESS FOR ITS ADMINISTRATION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1992-07-29 | — | — | EP | disclosed |
| EP-0187297-B1 | ALKOXY METHYL ETHER AND ALKOXY METHYL ESTER DERIVATIVES | SYNTEX (U.S.A.) INC. (US) | 1991-08-21 | — | — | EP | disclosed |
| WO-1991007168-A1 | RIBOFLAVIN AS A TANNING ENHANCER | SCHERING-PLOUGH HEALTHCARE PRODUCTS, INC. (US) | 1991-05-30 | — | — | WO | disclosed |
| WO-1991007167-A1 | PROTEIN KINASE ACTIVATORS AS ENHANCERS OF MELANIN PRODUCTION | SCHERING-PLOUGH HEALTHCARE PRODUCTS, INC. (US) | 1991-05-30 | — | — | WO | disclosed |
| EP-0187297-A2 | Alkoxy methyl ether and alkoxy methyl ester derivatives | SYNTEX (U.S.A.) INC. (US) | 1986-07-16 | — | — | EP | disclosed |
| EP-0002062-B1 | CYCLIC ORGANOPHOSPHORUS COMPOUNDS, METHOD FOR THEIR PREPARATION AND THEIR USE | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1982-05-05 | — | — | EP | disclosed |
| EP-0002062-A1 | Cyclic organophosphorus compounds, method for their preparation and their use | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1979-05-30 | — | — | EP | disclosed |
| US-3960905-A | Diacylglycerophosphoric acid esters of aminoethanol and methylaminoethanol and method of preparing the same | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DT) | 1976-06-01 | — | — | US | disclosed |